dc.contributor.author | Harris, Patrick NA | |
dc.contributor.author | Pezzani, M. Diletta | |
dc.contributor.author | Gutierrez-Gutierrez, Belen | |
dc.contributor.author | Viale, Pierluigi | |
dc.contributor.author | Hsueh, Po-Ren | |
dc.contributor.author | Ruiz-Garbajosa, Patricia | |
dc.contributor.author | Venditti, Mario | |
dc.contributor.author | Tumbarello, Mario | |
dc.contributor.author | Navarro-Francisco, Carolina | |
dc.contributor.author | Calbo, Esther | |
dc.contributor.author | Akova, Murat | |
dc.contributor.author | Giamarellou, Helen | |
dc.contributor.author | Oliver, Antonio | |
dc.contributor.author | Almirante, Benito | |
dc.contributor.author | Gasch, Oriol | |
dc.contributor.author | Martinez-Martinez, Luis | |
dc.contributor.author | Schwaber, Mitchell J | |
dc.contributor.author | Daikos, George | |
dc.contributor.author | Pitout, Johann | |
dc.contributor.author | Pena, Carmen | |
dc.contributor.author | Hernandez-Torres, Alicia | |
dc.contributor.author | Doi, Yohei | |
dc.contributor.author | Perez, Federico | |
dc.contributor.author | Tuon, Felipe Francisco | |
dc.contributor.author | Tacconelli, Evelina | |
dc.contributor.author | Carmeli, Yehuda | |
dc.contributor.author | Bonomo, Robert A | |
dc.contributor.author | Pascual, Alvaro | |
dc.contributor.author | Paterson, David L | |
dc.contributor.author | Rodriguez-Bano, Jesus | |
dc.contributor.author | ESGBIS Grp | |
dc.contributor.author | REIPI Grp | |
dc.contributor.author | INCREMENT Grp | |
dc.date.accessioned | 2024-07-11T09:12:20Z | |
dc.date.available | 2024-07-11T09:12:20Z | |
dc.date.issued | 2017-11 | |
dc.identifier.citation | Harris Patrick N. A., Pezzani M. Diletta, Gutierrez-Gutierrez Belen, Viale Pierluigi, Hsueh Po-Ren, Ruiz-Garbajosa Patricia, et al. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. Int J Antimicrob Agents. 2017 Nov;50(5):664-672. Epub 2017 Aug 3. | en |
dc.identifier.issn | 0924-8579 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/9593 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20493 | |
dc.description.abstract | We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = 1482) in 12 countries from an observational study of BSI caused by ESBL-E or CPE were included. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of beta-lactam/beta-lactamase inhibitors (BLBLIs) or carbapenems, targeted use of BLBLIs for ESBL-E and use of targeted combination therapy for CPE. Compared with Spain, BLBLI use for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14-0.81), Greece (aOR 0.49, 95% CI 0.26-0.94) and Canada (aOR 0.31, 95% CI 0.11-0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11-2.25) and Turkey (aOR 2.09, 95% CI 1.14-3.81). Empirical carbapenem use was more likely in sites from Taiwan (aOR 1.73, 95% CI 1.03-2.92) and USA (aOR 1.89, 95% CI 1.053.39) and less likely in Italy (aOR 0.44, 95% CI 0.28-0.69) and Canada (aOR 0.10, 95% CI 0.01-0.74). Targeted BLBLIs for ESBL-E was more likely in Italian sites. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. Better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts. | en |
dc.description.sponsorship | PNAH is supported by an Australian Postgraduate Award from the University of Queensland (Brisbane, QLD, Australia). The study was funded by Planes Nacionales de I+D+i 2008-2011 / 2013-2016 and Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI DR12/0015/0010, RD16/0016/0001, RD16/0016/0009, RD12/0015/0001, RD16/0016/0010, RD12/0015/0013, RD16/0016/0002, RD12/0015/0009, RD16/0016/0008, RD12/0015/0002, RD16/0016/0005, RD12/0015/0008, RD16/0016/0004, RD12/0015/0006, RD16/0016/0006, RD12/0015/0014, RD16/0016/0003, RD12/0015/0003, RD16/0016/0007, RD12/0015/0019, RD16/0016/0011, RD12/0015/0004, RD12/0015/0012 and RD16/0016/0014)cofinanced by European Development Regional Fund A way to achieve Europe, Operative program Intelligent Growth 2014-2020. BG-G, JR-B, AP and YC also received funds from the COMBACTE-CARE project [grant agreement 115620], Innovative Medicines Initiative (IMI), the European Union's Seventh Framework Programme [FP7/2007-2013] and in-kind contributions from EFPIA companies. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Elsevier | en |
dc.type.hasVersion | SMUR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Extended-spectrum beta-lactamase | |
dc.subject | Carbapenemase | |
dc.subject | Carbapenems | |
dc.subject | beta-Lactam/beta-lactamase inhibitor | |
dc.subject | Escherichia coli | |
dc.subject | Klebsiella pneumoniae | |
dc.subject.mesh | Aged, 80 and over | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Drug Resistance, Multiple, Bacterial | * |
dc.subject.mesh | Enterobacteriaceae Infections | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Enterobacteriaceae | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Global Health | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Sepsis | * |
dc.subject.mesh | beta-Lactamase Inhibitors | * |
dc.subject.mesh | beta-Lactams | * |
dc.subject.mesh | Retrospective Studies | * |
dc.title | Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study | en |
dc.type | research article | en |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.identifier.pubmedID | 28782704 | es_ES |
dc.format.volume | 50 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 664-672 | es_ES |
dc.identifier.doi | 10.1016/j.ijantimicag.2017.08.005 | |
dc.identifier.e-issn | 1872-7913 | es_ES |
dc.relation.publisherversion | https://dx.doi.org/10.1016/j.ijantimicag.2017.08.005 | en |
dc.identifier.journal | International Journal of Antimicrobial Agents | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Farmacorresistencia Bacteriana Múltiple | * |
dc.subject.decs | Salud Global | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Sepsis | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Enterobacteriaceae | * |
dc.subject.decs | Infecciones por Enterobacteriaceae | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Anciano de 80 o más Años | * |
dc.subject.decs | Inhibidores de beta-Lactamasas | * |
dc.subject.decs | beta-Lactamas | * |
dc.subject.decs | Estudios Retrospectivos | * |
dc.subject.decs | Adulto | * |
dc.identifier.scopus | 2-s2.0-85031115305 | |
dc.identifier.wos | 414070900009 | |
dc.identifier.pui | L618762051 | |